Analysts Set SAB Biotherapeutics, Inc. (NASDAQ:SABS) PT at $12.00

Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) have received a consensus recommendation of “Moderate Buy” from the eleven brokerages that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and nine have given a buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $12.00.

Several research analysts have weighed in on the company. Rodman & Renshaw restated a “buy” rating and issued a $13.00 price target on shares of SAB Biotherapeutics in a research note on Monday, May 11th. Citigroup assumed coverage on shares of SAB Biotherapeutics in a research report on Friday, May 22nd. They set a “buy” rating and a $11.00 price objective on the stock. Weiss Ratings restated a “sell (d+)” rating on shares of SAB Biotherapeutics in a research report on Wednesday, July 8th. Barclays assumed coverage on shares of SAB Biotherapeutics in a research note on Wednesday, June 24th. They set an “overweight” rating and a $13.00 target price for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of SAB Biotherapeutics in a report on Monday, June 15th.

SAB Biotherapeutics Price Performance

Shares of SAB Biotherapeutics stock opened at $3.58 on Friday. The company has a market capitalization of $273.73 million, a price-to-earnings ratio of -1.70 and a beta of 0.52. The company has a quick ratio of 11.45, a current ratio of 11.45 and a debt-to-equity ratio of 0.01. The stock’s 50-day simple moving average is $3.69 and its 200-day simple moving average is $3.85. SAB Biotherapeutics has a 52 week low of $1.85 and a 52 week high of $5.15.

SAB Biotherapeutics (NASDAQ:SABS) last released its earnings results on Tuesday, May 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.15). As a group, analysts expect that SAB Biotherapeutics will post -1.19 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. PNC Financial Services Group Inc. purchased a new stake in shares of SAB Biotherapeutics in the first quarter worth about $29,000. State of Wyoming purchased a new position in SAB Biotherapeutics during the 4th quarter valued at approximately $34,000. State Street Corp purchased a new position in SAB Biotherapeutics during the 4th quarter valued at approximately $49,000. Fifth Lane Capital LP bought a new stake in SAB Biotherapeutics in the 4th quarter worth approximately $56,000. Finally, ADAR1 Capital Management LLC bought a new stake in SAB Biotherapeutics in the 3rd quarter worth approximately $30,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.